Menu Search
Equities

Novozymes A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NSIS B:CPH

Novozymes A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)432.00
  • Today's Change3.60 / 0.84%
  • Shares traded526.52k
  • 1 Year change+8.62%
  • Beta0.5726
Data delayed at least 15 minutes, as of Sep 16 2026 15:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Sep-25
  • 18-Jun-26
  • 16-Jul-26
  • 20-Aug-26
  • 10-Sep-26
Select bar for recommendation details.
Recommendations10-Sep-26
Buy5
Outperform11
Hold2
Sell0
Strong Sell0

Share price forecast in EUR

The 14 analysts offering 12 month price targets for Novozymes A/S have a median target of 500.11, with a high estimate of 540.47 and a low estimate of 414.14. The median estimate represents a 15.77% increase from the last price of 432.00.
High25.1%540.50
Med15.8%500.13
Low-4.1%414.16

Dividends in EUR

In 2025, Novozymes A/S reported a dividend of 0.87 EUR, which represents a 4.67% increase over last year. The 14 analysts covering the company expect dividends of 0.95 EUR for the upcoming fiscal year, an increase of 9.27%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)4.67%
More ▼

Earnings history & estimates in EUR

On Aug 19, 2026, Novozymes A/S reported 2nd quarter 2026 earnings of 0.52 per share. This result exceeded the 0.40 expectation of the one analyst covering the company and exceeded last year's 2nd quarter results by 10.64%.
The next earnings announcement is expected on Nov 05, 2026.
Average growth rate+3.55%
Novozymes A/S reported annual 2025 earnings of 1.49 per share on Feb 25, 2026.
Average growth rate+1.09%
More ▼

Revenue history & estimates in EUR

Novozymes A/S had 2nd quarter 2026 revenues of 1.12bn. This bettered the 1.10bn consensus of the 4 analysts covering the company. This was 3.58% above the prior year's 2nd quarter results.
Average growth rate+2.54%
Novozymes A/S had revenues for the full year 2025 of 4.16bn. This was 5.38% above the prior year's results.
Average growth rate+22.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.